Investment Rating - The report maintains a "Strong Buy" investment rating for the company [2][3]. Core Views - The company achieved a revenue of 7.88 billion yuan in the first half of 2025, representing a year-on-year growth of 10.5%, and an adjusted net profit of 410 million yuan, up 14.6% year-on-year, indicating robust revenue growth and profit exceeding expectations [2][6]. - The long-term profit growth potential is viewed positively due to the company's solid market competitiveness and ongoing expansion of its store network [2][6]. Financial Performance Summary - Revenue projections for the company are as follows: - 2023: 13.601 billion yuan - 2024: 14.759 billion yuan (growth of 8.5%) - 2025E: 16.364 billion yuan (growth of 10.9%) - 2026E: 17.737 billion yuan (growth of 8.4%) - 2027E: 19.106 billion yuan (growth of 7.7%) [3][8]. - Adjusted net profit estimates are: - 2023: 481 million yuan - 2024: 624 million yuan (growth of 29.7%) - 2025E: 786 million yuan (growth of 25.9%) - 2026E: 899 million yuan (growth of 14.4%) - 2027E: 1.051 billion yuan (growth of 16.9%) [3][8]. - The company’s earnings per share (Non-GAAP) are projected to be: - 2023: 0.59 yuan - 2024: 0.76 yuan - 2025E: 0.96 yuan - 2026E: 1.10 yuan - 2027E: 1.28 yuan [3][9]. Market Position and Expansion - As of the first half of 2025, the company has expanded its store network to 7,205 locations, a net increase of 894 stores year-on-year, with a coverage rate of 70% in counties with over 20,000 passenger vehicles [6][8]. - The company has seen a 23.8% year-on-year increase in transaction users on its app, reaching 26.5 million, with an average monthly active user count of 13.5 million, up 17.5% year-on-year [6][8]. Valuation - The target valuation for the company is set at 26.3 HKD per share, with the current stock price at 20.74 HKD [3][4].

Investment Rating - The investment rating for WuXi Biologics (02269.HK) is "Buy" (maintained) [4][13] Core Views - The company achieved a robust revenue growth of 16.08% year-on-year in H1 2025, with total revenue reaching 9.953 billion yuan and a net profit of 2.339 billion yuan, reflecting a significant increase of 56.05% [4] - The company has raised its full-year revenue guidance for 2025 to a growth range of 14%-16%, supported by a backlog of unfulfilled orders amounting to approximately 20.34 billion USD [4] - The report highlights the strong growth momentum in preclinical services and anticipates future growth in CMO (Contract Manufacturing Organization) business [5] Financial Performance - In H1 2025, the company reported a gross margin of approximately 42.73%, an increase of about 3.6 percentage points year-on-year [4] - The adjusted net profit for H1 2025 was 2.840 billion yuan, representing a year-on-year growth of 11.60% [4] - The company’s earnings per share (EPS) for 2025-2027 are projected to be 1.1, 1.3, and 1.5 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 26.7, 23.9, and 19.5 times [4] Business Growth and Strategy - The preclinical business achieved revenue of 4.147 billion yuan in H1 2025, marking a year-on-year growth of approximately 35.2% [5] - The company has a total of 864 projects in various stages, with 429 in preclinical, 259 in Phase I, 85 in Phase II, 67 in Phase III, and 24 in commercialization [5] - WuXi Biologics is expanding its global capacity with five research service centers, eight drug development centers, and eight commercial production centers [6] Regional Performance - Revenue growth in North America was robust at 20.1%, while Europe and China saw growth rates of 5.7% and a decline of 8.5% respectively [6] - The company’s strategic expansion in North America is expected to continue driving revenue growth [6]

房地产/房地产服务 | 日期 | 2025/8/22 | | --- | --- | | 当前股价(港元) | 5.090 | | 一年最高最低(港元) | 5.630/3.040 | | 总市值(亿港元) | 160.32 | | 流通市值(亿港元) | 160.32 | | 总股本(亿股) | 31.50 | | 流通港股(亿股) | 31.50 | | 近 3 个月换手率(%) | 10.86 | 股价走势图 数据来源：聚源 -24% 0% 24% 48% 72% 96% 2024-08 2024-12 2025-04 2025-08 绿城服务 恒生指数 相关研究报告 《各业务毛利率均提升，在管面积双 位数增长—港股公司信息更新报告》 -2025.3.24 《盈利能力同比提升，在管面积稳健 增 长 — 港 股 公 司 信 息 更 新 报 告 》 -2024.8.26 ——港股公司信息更新报告 | 齐东（分析师） | 胡耀文（分析师） | 杜致远（联系人） | | --- | --- | --- | | qidong@kysec.cn | huyaowen@kysec.cn | duzhiyuan@kys ...

2025 年 8 月 25 日 公司研究 核心利润同比增长 25%，盈利改善趋势明确 ——绿城服务（2869.HK）2025 年中期业绩点评 事件：绿城服务 2025 年上半年核心经营利润同比增长 25%。 绿城服务发布 2025 年中期业绩报告，期内实现营收 93 亿元，同比增长 6.1%（公 司在 2024 年出售 MAG，计算同比时，对 2024 年上半年的收入数据进行重列， 使之不包含终止经营的业务，下同），实现毛利 18 亿元，同比增长 8.9%，毛 利率 19.5%，同比提升 0.5pct；核心经营利润（毛利-行政开支-营销开支）10.7 亿元，同比增长 25.3%；归母净利润 6.1 亿元，同比增长 22.6%。 点评：盈利改善趋势明确，经营业绩表现优秀，新拓项目质量较高。 1）主营业务稳健增长，经营业绩表现优秀。2025 年上半年公司物管/园区服务/ 咨询服务分别实现收入 66.3/13.6/13.0 亿元，同比+10.2%/-6.0%/+0.6%，物业 管理占总收入比重 71.4%，为公司业绩增长提供稳定支撑；园区服务中的居家 生活服务收入 1.2 亿元，同比减少 53.8%，主要由于旗下的 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's performance growth is in line with expectations, and it has announced a special dividend to reward shareholders [5] - The company is a leading player in the express logistics sector, with ongoing improvements in service quality and an expanding network of franchisees driving volume growth [7] - Despite short-term pressure on unit revenue due to weak demand, the company is expected to improve its unit gross margin through refined management and cost reductions [7] Financial Summary - For 2025, the company achieved a revenue of approximately 56.25 billion RMB, a year-on-year increase of 6.4%, and an adjusted net profit of about 4.76 billion RMB, up 10.7% year-on-year [7] - The company forecasts revenue growth from 11,576 million RMB in 2024 to 16,162 million RMB in 2027, with a compound annual growth rate (CAGR) of approximately 10.7% [8] - The projected net profit for 2025-2027 is 9.6 billion RMB, 10.6 billion RMB, and 12.6 billion RMB, respectively, with corresponding price-to-earnings (P/E) ratios of 9.1x, 8.2x, and 7.0x [7][8]

Investment Rating - The report maintains a "Buy" rating for the company, with a market price of HKD 21.42 and a sector rating of "Outperform" [1][3]. Core Insights - The company's core OTA (Online Travel Agency) business shows steady growth, with a revenue of RMB 4.669 billion in Q2 2025, representing a year-on-year increase of 10.0%. The adjusted net profit reached RMB 775 million, up 18.0% year-on-year. The report emphasizes the company's significant long-term competitive advantages [3][5][8]. Summary by Sections Financial Performance - In Q2 2025, the company achieved a revenue of RMB 4.669 billion, with an adjusted EBITDA of RMB 1.185 billion, reflecting a year-on-year growth of 29.7%. The adjusted net profit was RMB 775 million, up 18.0% year-on-year. The core OTA business generated revenue of RMB 4.01 billion, a 13.7% increase year-on-year [3][8]. - The company's gross margin stood at 65.0%, an increase of 0.4 percentage points year-on-year. Cost optimization led to improved profit margins, with the OTA operating profit margin at 26.7%, up 2.4 percentage points year-on-year [8]. Business Segments - Revenue from the accommodation, transportation ticketing, vacation, and other segments in Q2 2025 was RMB 1.37 billion, RMB 1.88 billion, RMB 660 million, and RMB 760 million, respectively. The transportation segment saw a nearly 30% year-on-year increase in international ticket volume [8]. Market Outlook - The domestic travel market remains robust, with cross-border travel continuing to grow. The company is well-positioned to benefit from the industry's growth in lower-tier markets and is actively expanding its business [5][8]. - The report projects the company's net profit for 2025-2027 to be RMB 2.707 billion, RMB 3.369 billion, and RMB 4.082 billion, with corresponding P/E ratios of 17.0, 13.7, and 11.3 times [5][7].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 780 million yuan for H1 2025, a year-on-year increase of 7.7%, with a net profit attributable to shareholders of -150 million yuan, narrowing the loss by 43.9% year-on-year. In Q2 2025, revenue reached 460 million yuan, up 24.1% year-on-year and 38.9% quarter-on-quarter, with a gross margin of 27.7%, exceeding expectations [7] - The gross margin for ADAS (Advanced Driver Assistance Systems) significantly increased, with Q2 2025 revenue at 270 million yuan, down 10.6% year-on-year but up 18.3% quarter-on-quarter. The shipment volume was 123,800 units, a year-on-year increase of 4.6% and a quarter-on-quarter increase of 28%. The average price per unit was 2,189 yuan, down 7.6% quarter-on-quarter, with a gross margin of approximately 19.4%, up 4.3 percentage points quarter-on-quarter [7] - The company has entered a high-growth phase in the general robotics sector, with Q2 2025 revenue of 150 million yuan, a year-on-year increase of 286.9% and a quarter-on-quarter increase of 101.4%. The shipment volume was 34,400 units, a year-on-year increase of 631.9% and a quarter-on-quarter increase of 189.1%. The average price per unit was 4,273 yuan, down 30.3% quarter-on-quarter, with a gross margin of approximately 41.7%, down 10.4 percentage points quarter-on-quarter [7] - The company is expected to see a significant increase in its general robotics business and improve its overall gross margin. The net profit forecasts for 2025, 2026, and 2027 have been adjusted to -228 million yuan, 58 million yuan, and 379 million yuan, respectively. The price-to-sales ratios for 2025, 2026, and 2027 are projected to be 8.1, 5.2, and 4.1 times, respectively, indicating a strong long-term growth potential [7] Financial Summary - The total revenue forecast for 2025 is 2,171 million yuan, with a year-on-year growth rate of 31.63%. The net profit attributable to shareholders is expected to be -228 million yuan, with a significant improvement in profitability forecasted for subsequent years [1][8] - The gross margin is projected to improve to 26.21% in 2025, with further increases expected in the following years [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's main business performance is robust and exceeds expectations, with operational efficiency supporting a relatively stable net profit margin [8] - The company is positioned as the only listed entity under China Tobacco International, focusing on the import and export of tobacco leaf products, which are showing steady growth [8] - Despite short-term pressures on Brazilian operations and new tobacco products, there is potential for further integration of overseas industry chain resources [8] - The company has adjusted its profit forecasts upwards, expecting attributable net profits of HKD 9.4 billion, 10.4 billion, and 12.1 billion for 2025-2027, respectively [8] Financial Performance Summary - Total revenue for 2023 is projected at HKD 11,836 million, with a year-on-year growth of 42.19% [1] - The attributable net profit for 2023 is expected to be HKD 598.77 million, reflecting a year-on-year increase of 59.71% [1] - The earnings per share (EPS) for 2023 is estimated at HKD 0.87, with a price-to-earnings (P/E) ratio of 43.83 [1] - The company anticipates a total revenue of HKD 14,856 million for 2025, representing a year-on-year growth of 13.63% [1] - The attributable net profit for 2025 is projected at HKD 938.26 million, with a year-on-year growth of 9.90% [1] - The EPS for 2025 is expected to be HKD 1.36, with a P/E ratio of 27.97 [1]

证券研究报告 计算机 | IT 服务Ⅱ 港股|公司点评报告 hyzqdatemark 2025 年 08 月 24 日 郑嘉伟 SAC：S1350523120001 zhengjiawei@huayuanstock.com 于炳麟 SAC：S1350524060002 yubinglin@huayuanstock.com 联系人 市场表现： | 基本数据 | 2025 | 年 | 08 | 月 21 | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 11.47 | | | 一年内最高/最低（港 | | | | 12.22/4.01 | | | 元） | | | | | | | 总市值（百万港元） | | | | 16,411.44 | | | 流通市值（百万港元） | | | | 16,411.44 | | | 资产负债率（%） | | | | 76.29 | | | 资料来源：聚源数据 | | | | | | 伟仕佳杰(00856.HK) 投资评级： 买入（维持） ——东南亚区域高速增长，利润率回升，1H25 公司业绩超预期 投资要点 ...

Investment Rating - The report maintains a "Buy" rating for the company [7]. Core Insights - In H1 2025, the company's revenue increased by 6.4% year-on-year to 5.63 billion, and adjusted net profit grew by 10.7% to 480 million [2][4]. - In Q2 2025, revenue rose by 4.4% year-on-year to 3.04 billion, with adjusted net profit increasing by 5.8% to 230 million [2][4]. - The company announced its first interim and special dividend, with a total payout of 231 million Hong Kong dollars, corresponding to a 50% dividend payout ratio, which enhances shareholder returns [4]. Summary by Sections Financial Performance - For H1 2025, the company achieved a revenue of 5.63 billion, a 6.4% increase year-on-year, and an adjusted net profit of 480 million, reflecting a 10.7% growth [2][4]. - In Q2 2025, the revenue was 3.04 billion, up 4.4% year-on-year, while adjusted net profit reached 230 million, marking a 5.8% increase [2][4]. Market Strategy - The company is actively adjusting its competitive strategy in response to intensified competition in the less-than-truckload (LTL) industry, optimizing cargo weight structure to drive steady growth in cargo volume [2][8]. - The company reported a 6.3% year-on-year increase in cargo volume to 3.771 million tons in Q2 2025, despite a 1.9% decline in the price per kilogram to 0.81 [8]. Cost Management - In Q2 2025, the company's cost per kilogram increased by 0.03, leading to a decrease in gross profit per kilogram by 0.02 [8]. - The company experienced a rise in transportation costs by 1.4% and distribution costs by 6.0% year-on-year, while the increase in value-added service costs was notably higher at 54.2% [8]. Network Expansion - The number of secondary franchisees increased by 2,000 to 38,000, maintaining the company's leading position in the franchise express network [8]. - The average delivery time decreased by 5.3% year-on-year, and the rate of lost packages dropped by nearly 50% [8]. Dividend and Profitability Outlook - The company’s dividend yield is attractive at 5.3%, with projected net profits for 2025-2027 expected to be 880 million, 1.01 billion, and 1.19 billion respectively, corresponding to PE ratios of 9.6, 8.3, and 7.1 [8].